The properties of Rickettsia rickettsii purified from infected chicken yolk sacs or mouse L cell cultures by sucrose density gradient centrifugation in a zonal rotor were examined in various ways. Rickettsiae derived from both L cells and yolk sacs had similar compositions: about 12% nitrogen, 1.5% phosphorus, 5% carbohydrate, and 30% fatty acids. On a dry-weight basis, purified rickettsiae were at least 2,000 times as effective as a commercial spotted fever vaccine in protecting guinea pigs against infection with spotted fever rickettsiae and mice against death from toxin of R. rickettsii. Gradient-purified rickettsiae (0.6 Mg) induced a serological response in guinea pigs of the same magnitude as that stimulated by 1,600 Ag of the commercial vaccine. Gradient-purified rickettsiae had little group reactivity in complement fixation tests but became anti-complementary upon storage. Microagglutination and hemagglutination tests with the purified antigen gave promise of usefulness in diagnosis of spotted fever. These results suggest that zonal centrifugation may be a valuable procedure for the preparation of R. rickettsii vaccine and diagnostic reagent.
Recently we reported that the spotted fever rickettsia, Rickettsia rickettsii, could be obtained in a high state of purity from infected yolk sacs of chicken embryos or L cell tissue cultures by centrifugation in a linear sucrose gradient in a zonal rotor (1) . Since the effects of such treatment on the biological properties were unknown, a study was undertaken to determine how well vaccination with purified rickettsiae would protect animals against challenge with virulent spotted fever rickettsiae or their toxin. Also, usefulness of the purified rickettsiae as a diagnostic reagent in various serological tests was investigated. In addition, the basic chemical composition of the rickettsiae was determined. Results of these studies are summarized in the following report.
MATERIALS AND METHODS
Animals. Approximately 400-g male Hartley strain guinea pigs, obtained locally, and 3-to 4-week-old male white mice of the Rocky Mountain Laboratory (RML) strain were used for our experiments.
Strains of rickettsiae. Egg-adapted R. rickettsii strain R, isolated from Dermacentor andersoni ticks collected in the Bitter Root Valley of western Montana, was used in the preparation of gradient-purified rickettsiae and "conventional" complement-fixing (CF) antigen by ether extraction of infected yolk sacs (see below) and as the challenge organism in toxicity tests and all but one protection test. The Sawtooth strain of R. rickettsii, also isolated from D. andersoni ticks collected in the Bitter Root Valley and since maintained in ticks, was used in the preparation of antiserum for serological tests. The Sheila Smith strain of R. rickettsii was utilized by our commercial source of vaccine and as the challenge organism in one of our protection tests. This strain was obtained from a patient in Missoula, Mont.
Rickettsiae of other species used for the preparation of antisera were the Simko strain of R. conorii, R. australis strain 32, R. akari strain 7, the Breinl strain of R. prowazekii, and California strain 805 of Coxiella burnetii in phase I. These strains have been maintained in eggs or ticks at RML for at least several years.
Antisera. Anti-rickettsial sera were prepared from blood collected from convalescent guinea pigs infected with yolk sac or tick suspensions containing the various rickettsiae. Antiserum to R. rickettsii, devoid of antibody to yolk sac antigens, was obtained 37 days after injection of a suspension of ticks containing infectious rickettsiae of the Sawtooth strain. There was no significant difference in the behavior of rickettsiae of the R and Sawtooth strains in CF tests. Guinea pig antiserum to C. burnetii was collected 3 weeks after infection, which followed subcutaneous inoculation with purified, ether-inactivated, Q fever rickettsiae by 3 weeks. Animals infected with R. akari and R. conorii were bled 1 month later, and those infected with R. prowazekii were bled 3 weeks later. R. australis antiserum was obtained from guinea pigs 2 weeks after the last of six weekly inoculations of living rickettsiae. Preparation of the anti-yolk sac serum was-described previously (1 (11) . After overnight incubation, 0.025 ml of aqueous acridine orange (1:5,000) was added to each well to make the rickettsiae more readily visible.
The hemagglutination (HA) procedure described by Chang (6) for typhus rickettsiae was adapted for use with spotted fever rickettsiae. For our study, gradient-purified lyophilized rickettsiae were suspended in saline ( The mouse protection test for potency assay of the gradient-purified rickettsiae and the commercial vaccine was also used (3, 5) . Three-week-old mice were inoculated intraperitoneally with 0.5-ml volumes of graded doses of the preparations in PBS. Seven days later the mice were inoculated intravenously with a yolk sac suspension containing 2 50% lethal doses (LD,0) of R. rickettsii toxin. (The LD50 dose was determined in 28-day-old normal mice.) Deaths were recorded at 24 h, and the dose protecting 50'7 of the mice from the lethal effects of the toxin was calculated by the method of Reed and Muench (20) .
Chemical analyses. Nitrogen was determined by the procedure of Johnson (14) . Total carbohydrate was estimated by the tryptophan method (8), using glucose as a standard. Phosphorus was determined colorimetrically after digestion with sulfuric acid and hydrogen peroxide (9) , and esterified fatty acids and amide-linked fatty acids, with palrnitic acid as a standard, were determined by the method of Haskins (12) . Total protein released from the rickettsiae heated to 100 C with NaOH was determined colorimetrically after reduction of the Folin-Ciocalteau reagent (13 Diagnostic reagent. The suitability of R. rickettsii purified by density gradient zonal centrifugation as antigen in serological tests was investigated.
Hemagglutinin and agglutinin titers of sera obtained from guinea pigs 3 weeks after infection with R. rickettsii are presented in Table 2 . were positive in all tests except the CF test using gradient-purified R. rickettsii. Six sera, as no. 4, reacted only in the two agglutination tests, and three sera, including no. 7, reacted only in the CF test using the ether-extracted antigen and in the HA test.
Guinea pig sera reacted more uniformly in the various tests. The specific antiserum (no. 8) had similar titers in all tests, and the anti-C. burnetii and R. prowazekii sera did not crossreact with the R. rickettsii antigens. Yolk sac antigen was detected only in the ether-extracted yolk sac suspension.
To determine whether the gradient-purified rickettsiae still possessed CF group antigen, the purified rickettsiae, as well as the conventional yolk sac antigen, were tested against guinea pig antisera to several rickettsiae of the spotted fever group. Compared with conventional yolk sac antigen, the content of the CF group antigen on the purified rickettsiae was considerably reduced (Table 4) .
Some information relating to stability of the gradient-purified antigens was obtained. Preparations stored at 4 C in saline containing merthiolate (1:10,000) performed well in the CF test when freshly prepared, but 2 months later these preparations were too anti-complementary to use. In contrast, the same type of antigen appeared unchanged in MA tests when last tested 3 months after preparation. Antigen prepared for the HA test was not affected by storage at 4 C for 9 months.
Antibody response of guinea pigs. The antibody responses of five to six guinea pigs inoculated with single doses of either 1,600 mg (dry weight) of the commercial vaccine or 0.6 ,ug (dry weight) of gradient-purified R. rickettsii were measured by CF, MA, and HA tests. Fourfold lower doses of the antigens were used in an earlier experiment, but the levels of antibody detected were even lower than those reported here. Agglutinin titers in sera from animals inoculated with either antigen reached a peak at about 5 days and then quickly dropped (Fig. 1) . HA days and then dropped off more slowly. For the doses used, responses to the gradient-purified antigen were somewhat greater than to the commercial vaccine.
Immunogenicity. The quantities of R. rickettsii purified from both yolk sacs and L cells required to protect guinea pigs against infection with spotted fever rickettsiae are presented in Table 5 . Purified rickettsiae in aqueous suspension protected best (no. 2 and 4); PD5O values for yolk sac and L cell-cultivated rickettsiae were 3 to 4 logs lower than that for the commercial vaccine (no. 5). For reasons not for microagglutination and yet clear, lyophilization adversely affected protective potency, but the lyophilized preparations (no. 1 and 3), on a weight basis, were still at least 2 logs better than the commercial vaccine (no. 5).
Since the commercial vaccine used in the above experiment was prepared from the Sheila Smith strain and rickettsiae of the R strain were used for challenge, PD,0 values for gradientpurified rickettsiae (aqueous suspension of L cell-grown rickettsiae) and the commercial vaccine in guinea pigs challenged with the Sheila Smith strain were determined. Values of 0.0081 and 82.7 ,g, respectively, were obtained, which indicated that the difference in potency of the two preparations was probably not related to the difference in strains used for challenge.
A similar relationship was observed in experiments in which mice vaccinated with graded doses of the various preparations were challenged with 2 LD,0 of toxin of R. rickettsii (Table 6 ). Aqueous suspensions of gradientpurified rickettsiae (no. 2 and 4) were about 5,000 times more protective than was the commercial vaccine (no. 5), and the lyophilized preparations (no. 1 and 3) were about 25 to 45 times more potent.
DISCUSSION
Results from the various studies of R. rickettsii purified by density gradient zonal centrif- ugation indicate that the purification procedure did not adversely affect the properties of the organisms. Indeed, potency of the purified rickettsiae in the bioassays was very high. Also, gross chemical composition of the purified rickettsiae was similar to that reported for other rickettsiae (2, 17, 18, 23) .
Compared with the presently available commercial vaccine, the gradient-purified rickettsiae were extremely potent in our bioassays. On a dry-weight basis, 2,000 to 6,000 times more commercial vaccine than gradient-purified rickettsiae was required to provide the same degree of protection to guinea pigs against infection with spotted fever rickettsiae. Similar quantities of each preparation protected mice against the lethal effects of the toxin of R. rickettsii. Possible reasons for the disparity in potency are (i) contamination of the commercial vaccine with tissue from the chicken embryo, (ii) inactivation of R. rickettsii immunogen(s) during preparation of the commercial vaccine, and (iii) inactivation of R. rickettsii immunogen(s) in commercial vaccine during storage.
It is unfortunate that our stock of the Sheila Smith strain of R. rickettsii was not well adapted to eggs so that we could conveniently use that strain for our gradient-purified rickettsiae and toxin, because questions may arise regarding the validity of our comparisons of results of tests in which animals were inoculated with either purified rickettsiae of the R strain or commercial vaccine derived from the Sheila Smith strain and subsequently tested with the R strain only. However, certain considerations may make these comparisons more acceptable.
In the case of vaccine potency, we demonstrated that gradient-purified rickettsiae of the R strain were clearly as superior to the commercial vaccine in guinea pigs challenged with the Sheila Smith strain as in those challenged with the R strain. Also, Bell and Stoenner (4) showed that three pathogenic strains of R. rickettsii Since our results demonstrated that rickettsiae purified from yolk sacs by density gradient zonal centrifugation were highly immunogenic, we would agree with their suggestion that the reason for the superiority of the duck embryo cell vaccine over the yolk sac vaccine is due in part to the greater number of rickettsiae present in infected duck embryo cells rather than to a greater inherent immunogenicity per rickettsial cell.
In the second study, DuPont et al. (10) reported that commercial vaccine provided very limited protection to humans. Twelve of 13 volunteers who received commercial vaccine 3 to 6 months before intradermal challenge with R. rickettsii developed clinical spotted fever. However, compared with unvaccinated controls the incubation period was lengthened and the duration of fever was decreased. No amelioration of disease was observed in two individuals vaccinated 16 months before challenge. In contrast, no symptoms of disease were noted in six individuals challenged 4 to 17 months after experimental infection. Although gradient-purif'ied rickettsiae were clearly superior to commercial vaccine in our experiments with guinea pigs and mice, without field trials one cannot conclude that the purified rickettsiae would afford practical immunity to humans.
From our experience with two kinds of tests to evaluate the efficacy of spotted fever vaccines, we 
